Margetuximab Versus Trastuzumab in Patients With Advanced Breast Cancer: A Cost-effectiveness Analysis

被引:9
|
作者
Kelly, Bridget N. [1 ]
Webster, Alexandra J. [1 ]
Lamb, Leslie [2 ]
Spivey, Tara [1 ]
Korotkin, Jenna E. [1 ]
Henriquez, Anthony [1 ]
Gadd, Michele A. [1 ]
Hughes, Kevin S. [1 ]
Lehman, Constance R. [2 ]
Smith, Barbara L. [1 ]
Specht, Michelle C. [1 ]
机构
[1] Massachusetts Gen Hosp, Div Surg Oncol, Yawkey 7,55 Fruit St, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Radiol, Boston, MA 02114 USA
关键词
Breast conserving surgery; Magnetic seed localization; Wireless localization; Lumpectomy; Preoperative; identification (RFID) seeds; nonradioactive radar localization (SAVI; ONCOLOGY CONSENSUS GUIDELINE; CONSERVING SURGERY; AMERICAN SOCIETY; LOCALIZATION; IRRADIATION; MARGINS; LESIONS; SYSTEM;
D O I
10.1016/j.clbc.2022.01.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Magnetic seed is an alternative to wires for localization of nonpalpable breast lesions that uses a wireless detector probe to guide the surgeon to an implanted magnetic seed. Operative time, specimen volume, postoperative opioid administration, and re-excision rate were compared between the 2 cohorts. We found magnetic seeds to be a feasible alternative to wires with regard to surgical outcomes. Introduction: Magnetic seeds have emerged as an alternative to wires for localization of nonpalpable breast lesions. The purpose of this study was to evaluate the utility of magnetic seeds compared to wires for preoperative localization. Materials and Methods: A retrospective cohort analysis of magnetic seed localization (MSL) and wire localization (WL) excisional biopsies and lumpectomies performed at a single institution was conducted. Indication, age, BMI, number of markers, procedure type, operative time, and postoperative opioid administration were reviewed. Impact of localization method on operative time, specimen volume, postoperative opioid administration, and re-excision rate were assessed. Results: A total of 608 MSL procedures in 601 patients were compared to 628 WL procedures in 620 patients. MSL excisional biopsies were significantly longer (37.0 minutes) than WL excisional biopsies (31.9 minutes, P < .001), but in lumpectomies without axillar y surger y, MSL procedures (42.3 minutes) were significantly shorter than WL procedures (46.9 minutes, P = .017). Significantly less tissue was excised during MSL lumpectomies (68.5 cm 3 ) and excisional biopsies (32.3 cm 3 ) than WL lumpectomies (78.1 cm 3 , P = .039) and excisional biopsies (38.7 cm 3 , P = .018). Postoperative opioid administration was similar for MSL and WL procedures ( P = .076). Re-excision rates for MSL lumpectomies were significantly higher for ductal carcinoma in situ (35.3% MSL vs. 18.5% WL, P = .013), but were similar for invasive carcinoma (14.4% MSL vs. 17.7% WL, P = .290). Logistic regression analysis showed no association between localization method and re-excision (OR 1.007, 95% CI 0.681-1.488; P = .973). Conclusion: MSL is a feasible alternative to WL for excision of nonpalpable breast lesions with regard to surgical outcomes.
引用
收藏
页码:E700 / E707
页数:8
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS OF TREATMENT WITH TRASTUZUMAB IN PATIENTS WITH EARLY BREAST CANCER FROM THE PORTUGUESE SOCIETAL PERSPECTIVE
    Macedo, A.
    Monteiro, I
    Ray, J. A.
    Cirrincione, A.
    Andrade, S.
    Pereira, C.
    VALUE IN HEALTH, 2008, 11 (06) : A472 - A472
  • [32] Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china
    Qiaoping Xu
    Li Yuanyuan
    Zhu Jiejing
    Liu Jian
    Li Qingyu
    Chen Lingya
    Luo Ying
    Shi Changchen
    Li Yangling
    Yan Wei
    Cost Effectiveness and Resource Allocation, 19
  • [33] Cost-effectiveness of talazoparib for patients with locally advanced or metastasized breast cancer in Germany
    Schwarz, Florian
    Arefian, Habibollah
    Hartmann, Michael
    Runnebaum, Ingo
    PLOS ONE, 2022, 17 (12):
  • [34] Cost-effectiveness analysis of triptorelin versus leuprolide in the treatment of advanced prostate cancer
    Ravasio, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2016, 3 (03) : 150 - 154
  • [35] Cost-effectiveness analysis of trastuzumab emtansine for second-line treatment of HER2+advanced breast cancer in Singapore
    Wong, Wei Han Melvin
    Ng, Raymond
    Aziz, Mohamed Ismail Abdul
    Ong, Benjamin Shao-Kiat
    Ng, Kwong
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2025,
  • [36] Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer
    Perez-Ellis, Carole
    Goncalves, Anthony
    Jacquemier, Jocelyne
    Marty, Michel
    Girre, Veronique
    Roche, Henri
    Brain, Etienne
    Moatti, Jean-Paul
    Viens, Patrice
    Le Corroller-Soriano, Anne-Gaelle
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2009, 32 (05): : 492 - 498
  • [37] Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
    Lee Cheng Phua
    Soo Chin Lee
    Kwong Ng
    Mohamed Ismail Abdul Aziz
    BMC Health Services Research, 20
  • [38] COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB plus DOCETAXEL VERSUS DOCETAXEL ALONE IN THE TREATMENT OF HER2+METASTATIC BREAST CANCER
    Athanasakis, K.
    Golna, C.
    Kyriopoulos, J.
    VALUE IN HEALTH, 2011, 14 (07) : A449 - A449
  • [39] Cost-effectiveness of capecitabine in combination with docetaxel versus docetaxel monotherapy in patients with advanced and/or metastatic breast cancer in France
    Lilliu, H
    Le Pen, C
    Priol, G
    Perez-Niddam, K
    Aultman, R
    Garrison, L
    VALUE IN HEALTH, 2003, 6 (06) : 626 - 626
  • [40] Cost-effectiveness analysis of atezolizumab in advanced triple-negative breast cancer
    Phua, Lee Cheng
    Lee, Soo Chin
    Ng, Kwong
    Abdul Aziz, Mohamed Ismail
    BMC HEALTH SERVICES RESEARCH, 2020, 20 (01)